MindMed's recent financing has closed after being upsized all the way to CAD$34.5 million.
Psychedelics
Magic Mushrooms Are Expanding Minds and Advancing an Emerging Field of Science
They’ve been credited in part for the musical and artistic revolutions of the late 1960s. According to some scientific opinions, they have potentially inspired early creativity in humans and our ancient ancestors.
Rotation Opportunity As Three Top Psychedelic Stocks Explode
Leading psychedelic stocks have gone ballistic in recent weeks. But where will investors find the NEXT multi-bagger opportunity?
Mind Cure (CSE: MCUR | OTC: MCURF) Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
The company is set to open a therapeutic health and training center in Kelowna, British Columbia in May of 2021
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Entheon has secured a supply of DMT for delivery to its drug research center (CHDR) in the Netherlands.
Mind Cure Announces its Research Program with Psychedelic Compounds
Mind Cure's initial R&D focus will be on psilocybin, ketamine and ibogaine. Researching both pain and mental health applications for psychedelics.
Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine completes its first commercial harvest of 20 kilograms of psilocybin mushrooms.
Champignon Brands Appoints Christopher Hobbs as Interim Chief Financial Officer
Champignon Brands names an interim CFO after Stephen Brohman resigns.
The Hottest Biotech In 2021
Warning: This is probably not for you.
Will ATAI’s IPO Help Or Hurt Compass Pathways?
ATAI Life Science's IPO in 2021 is expected to be another big industry catalyst. But one company that might NOT benefit is Compass Pathways.
Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering
Numinus announces a bought deal financing at CAD$0.68 cents.
Prominent Bitcoin Investor’s Next Monster Bet
One of Bitcoin’s most prominent investors is making a new monster bet.
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth
Cybin Corp acquires Adelia Therapeutics in an all-stock transaction valued at CAD$20.2 million.
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
Entheon discusses its new strategic investment in Wonder Scientific.
BIG Psychedelics Financings Powering Future Investor Profits
Nearly half a billion dollars has recently flooded into the coffers of psychedelic drug companies. That's enough capital to power a lot of growth.